# A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

> **NCT05975073** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 53 (actual)

## Conditions studied

- MTAP-null Non-Small-Cell Lung Cancer
- MTAP-null Solid Tumors

## Interventions

- **DRUG:** Anvumetostat
- **DRUG:** IDE397

## Key facts

- **NCT ID:** NCT05975073
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2026-02-25
- **Final completion:** 2026-03-26
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975073, "A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05975073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*